Nivolumab plus ipilimumab improve survival in advanced renal cell carcinoma

1. Amongst patients with advanced renal-cell carcinoma and an intermediate or poor prognosis, nivolumab plus ipilimumab was superior to sunitinib alone in improving overall survival. 2. Though not statistically compared, there was a lower incidence of grade three or four adverse events with nivolumab plus ipilimumab, although more patients in the combination therapy arm stopped []

New drug regimen reduces toxicities in patients with renal cancer


Findings of a 7-year study revolutionized the standard protocol for patient management by reducing toxicities for patients with metastatic renal cell carcinoma (mRCC).

Existing drug extends survival for patients with rare thymic carcinoma


Sunitinib, an agent approved for use in several cancers, could prove useful in treatment of thymic carcinoma when traditional chemotherapy fails.

Pazopanib tolerated best in kidney cancer study


A trial comparing pazopanib and sunitinib found pazopanib to have better safety and health-related quality-of-life profiles among persons with metastatic renal cell carcinoma.

Potential markers investigated for sunitinib response in patients with metastatic ccRCC


Markers in primary tumors such as CA9, CD31, CD34, and VEGFR1/2 might serve as predictors of a good response to sunitinib treatment in patients with metastatic clear cell renal carcinoma (ccRCC).

Sunitinib does not speed growth of renal cancer in humans

Animal studies have suggested that sunitinib may promote cancer growth and metastasis, but this does not appear to happen in humans.

Regorafenib prolongs survival in face of GI cancers

Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.

Targeted drug overcomes resistance in patients with rare sarcoma


Regorafenib, a new, targeted, oral drug, demonstrated the ability to control metastatic GIST, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies.

The role of sunitinib in the treatment of GIST

The role of sunitinib in the treatment of GIST

What is the role of sunitinib malate in the treatment of sarcomas?

How kidney cancer therapies could improve quality of life

Kidney cancer drugs in development could improve patients' quality of life and allow more effective treatment, according to Professor Robert Hawkins of Manchester University.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs